Novo Nordisk Stock Falls Over 20% on Revised Sales Forecast and Market Competition
-
最新报道：Novo Nordisk shares dropped over 20% after the pharmaceutical giant lowered its 2024 sales forecast, citing intensifying competition in the weight-loss drug market. The Danish company, maker of popular drugs Ozempic and Wegovy, now expects sales growth of 19-27% this year, down from previous projections. Analysts attribute the revised outlook to emerging rivals like Eli Lilly's Zepbound, which has gained significant market share. Despite the setback, Novo Nordisk remains a leader in the GLP-1 drug sector, with its products still dominating diabetes and obesity treatments globally. The stock decline erased approximately $50 billion from the company's market value.
下一篇
MicroStrategy Surged 2.51%—Can This Bitcoin-Holding Giant Sustain Its Momentum?
- MicroStrategy's stock rose 2.51% as the Bitcoin-holding giant continues to maintain strong...
24小时热点
热点专题
407106